Proteomic analysis of soft tissue sarcoma

International Journal of Clinical Oncology

Volumn 16, Issue 2, 2011, Pages 92-100

  Suehara, Yoshiyuki ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

2D DIGE; Proteomics; Soft tissue sarcomas

Indexed keywords

BIOLOGICAL MARKER; CELL PROTEIN; PFETIN; POTASSIUM CHANNEL; SECERNIN 1; UNCLASSIFIED DRUG;

DISEASE ASSOCIATION; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; HUMANS; PROTEOMICS; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 79959825318     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0203-9     Document Type: Review

References (53)

1. Fletcher CDM, Unni KK, Mertens F (2002) World health organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. IARC Press, Lyon
2. Tschoep K, Kohlmann A, Schlemmer M et al (2007) Gene expression profiling in sarcomas. Crit Rev Oncol Hematol 63:111-124
3. Francis P, Namlos HM, Muller C et al (2007) Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 8:73
4. Allander SV, Illei PB, Chen Y et al (2002) Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 161:1587-1595 (Pubitemid 35265519)
5. Nakagawa Y, Numoto K, Yoshida A et al (2006) Chromosomal and genetic imbalances in synovial sarcoma detected by conventional and microarray comparative genomic hybridization. J Cancer Res Clin Oncol 132:444-450
6. Lee YF, John M, Falconer A et al (2004) A gene expression signature associated with metastatic outcome in human leiomyosarcomas. Cancer Res 64:7201-7204 (Pubitemid 39372051)
7. Nielsen TO, West RB, Linn SC et al (2002) Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359:1301-1307 (Pubitemid 34310636)
8. Nagayama S, Katagiri T, Tsunoda T et al (2002) Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res 62:5859-5866 (Pubitemid 35204746)
9. Nakayama R, Mitani S, Nakagawa T et al (2010) Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type. Am J Surg Pathol 34:1599-1607
10. Antonescu CR (2008) Molecular profiling in the diagnosis and treatment of high grade sarcomas. Ultrastruct Pathol 32:37-42
11. Kawai A, Kondo T, Suehara Y et al (2008) Global protein-expression analysis of bone and soft tissue sarcomas. Clin Orthop Relat Res 466:2099-2106
12. Nielsen TO (2006) Microarray analysis of sarcomas. Adv Anat Pathol 13:166-173
13. Suehara Y, Kondo T, Fujii K et al (2006) Proteomic signatures corresponding to histological classification and grading of soft-tissue sarcomas. Proteomics 6:4402-4409 (Pubitemid 44277041)
14. Gygi SP, Rochon Y, Franza BR et al (1999) Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19:1720-1730 (Pubitemid 29098230)
15. Chen G, Gharib TG, Huang CC et al (2002) Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 1:304-313
16. Yanagisawa K, Shyr Y, Xu BJ et al (2003) Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362:433-439 (Pubitemid 36999706)
17. Alaiya AA, Franzen B, Hagman A et al (2002) Molecular classification of borderline ovarian tumors using hierarchical cluster analysis of protein expression profiles. Int J Cancer 98:895-899 (Pubitemid 34286687)
18. Reyzer ML, Caldwell RL, Dugger TC et al (2004) Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Res 64:9093-9100 (Pubitemid 39665523)
19. Cui JW, Wang J, He K et al (2004) Proteomic analysis of human acute leukemia cells: insight into their classification. Clin Cancer Res 10:6887-6896 (Pubitemid 39383038)
20. Varambally S, Yu J, Laxman B et al (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8:393-406 (Pubitemid 41579834)
21. Suehara Y, Kikuta K, Nakayama R et al (2010) GST-P1 as a histological biomarker of synovial sarcoma revealed by proteomics. Proteomics Clin Appl 3:623-634
22. Suehara Y, Kikuta K, Nakayama R et al (2010) Anatomic site-specific proteomic signatures of gastrointestinal stromal tumors. Proteomics Clin Appl 3:584-596
23. Takahashi T, Naka T, Fujimoto M et al (2008) Aberrant expression of glycosylation in juvenile gastrointestinal stromal tumors. Proteomics Clin Appl 2:1246-1254
24. Li Y, Liang Q, Wen YQ et al (2010) Comparative proteomics analysis of human osteosarcomas and benign tumor of bone. Cancer Genet Cytogenet 198:97-106
25. Li Y, Dang TA, Shen J et al (2006) Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics 6:3426-3435 (Pubitemid 43886158)
26. Fetsch PA, Simone NL, Bryant-Greenwood PK et al (2002) Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol 118:870-876 (Pubitemid 37047827)
27. Kikuta K, Tochigi N, Shimoda T et al (2009) Nucleophosmin as a candidate prognostic biomarker of Ewing's sarcoma revealed by proteomics. Clin Cancer Res 15:2885-2894
28. Suehara Y, Kondo T, Seki K et al (2008) Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin Cancer Res 14:1707-1717 (Pubitemid 351469455)
29. Holt GE, Schwartz HS, Caldwell RL (2006) Proteomic profiling in musculoskeletal oncology by MALDI mass spectrometry. Clin Orthop Relat Res 450:105-110 (Pubitemid 44342123)
30. Suehara Y, Tochigi N, Kubota D et al (2011) Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics. J Proteomics (in press)
31. Kang HJ, Koh KH, Yang E et al (2006) Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDG-FRA mutations. Proteomics 6:1151-1157
32. Kikuta K, Tochigi N, Saito S et al (2010) Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics. Proteomics Clin Appl 4:560-567
33. Conrad DH, Goyette J, Thomas PS (2008) Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Intern Med 23(Suppl 1):78-84 (Pubitemid 350295398)
34. Alessandro R, Fontana S, Kohn E et al (2005) Proteomic strategies and their application in cancer research. Tumori 91:447-455
35. Granville CA, Dennis PA (2005) An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 32:169-176 (Pubitemid 40387642)
36. Kondo T, Hirohashi S (2006) Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nat Protoc 1:2940-2956
37. Kondo T, Hirohashi S (2009) Application of 2D-DIGE in cancer proteomics toward personalized medicine. Methods Mol Biol 577:135-154
38. Nakayama R, Nemoto T, Takahashi H et al (2007) Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 20:749-759 (Pubitemid 46933446)
39. Suda T, Tsunoda T, Uchida N et al (2006) Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci 97:411-419
40. Ueda T, Aozasa K, Tsujimoto M et al (1988) Prognostic significance of mast cells in soft tissue sarcoma. Cancer 62:2416-2419
41. Oda Y, Hashimoto H, Tsuneyoshi M et al (1993) Survival in synovial sarcoma. A multivariate study of prognostic factors with special emphasis on the comparison between early death and long-term survival. Am J Surg Pathol 17:35-44 (Pubitemid 23011318)
42. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056 (Pubitemid 32267975)
43. van der Zwan SM, DeMatteo RP (2005) Gastrointestinal stromal tumor: 5 years later. Cancer 104:1781-1788
44. Kang HJ, Nam SW, Kim H et al (2005) Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene 24:1066-1074 (Pubitemid 40313883)
45. Antonescu CR, Viale A, Sarran L et al (2004) Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 10:3282-3290 (Pubitemid 38685432)
46. El-Rifai W, Sarlomo-Rikala M, Andersson LC et al (2000) DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res 60:3899-3903 (Pubitemid 32204584)
47. Pruneri G, Mazzarol G, Fabris S et al (2003) Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation. Mod Pathol 16:886-892 (Pubitemid 37152018)
48. Koon N, Schneider-Stock R, Sarlomo-Rikala M et al (2004) Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 53:235-240 (Pubitemid 38125511)
49. Kikuta K, Gotoh M, Kanda T et al (2009) Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilities. Jpn J Clin Oncol 40:60-72
50. Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620-625 (Pubitemid 351264357)
51. Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-632 (Pubitemid 351264358)
52. Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127-1134 (Pubitemid 39296599)
53. Resendes BL, Kuo SF, Robertson NG et al (2004) Isolation from cochlea of a novel human intronless gene with predominant fetal expression. J Assoc Res Otolaryngol 5:185-202 (Pubitemid 38833309)